

Applicants : Michael J. Elliott et al.  
Serial No. : 08/602,272  
Filed : February 16, 1996  
Page 2

**In the Claims**

Please amend the claims by replacing all prior listings of claims with the listing of claims below pursuant to 37 C.F.R. §1.121:

**Listing of the Claims:**

1-5. (Cancelled)

6. (Currently Amended) A method of treating ~~thrombosis~~ a thrombotic disorder in a subject in need thereof ~~diagnosed as suffering from thrombosis~~ comprising administering a therapeutically effective amount of an anti-tumor necrosis factor antibody or antigen-binding fragment thereof to the subject, wherein the thrombotic disorder is selected from the group consisting of: a thromboembolic disorder, an ischemic event, stroke, acute myocardial infarction, deep vein thrombosis and thrombophlebitis.

7-8. (Cancelled)

9. (Previously Presented) The method of claim 6, wherein the antibody is selected from the group consisting of a humanized antibody and a resurfaced antibody or antigen-binding fragment thereof.

10. (Previously Presented) The method of claim 6, wherein the antibody binds to an epitope included in amino acid residues of about 87-108 (SEQ ID NO:1) or about 59-80 (SEQ ID NO:2) of hTNF $\alpha$ .

11. (Cancelled)

12. (Previously Presented) The method of claim 6, wherein the

Applicants : Michael J. Elliott et al.  
Serial No. : 08/602,272  
Filed : February 16, 1996  
Page 3

antibody is a chimeric antibody, said chimeric antibody comprising (a) a non-human variable region specific for TNF or an antigen-binding portion thereof and (b) a human constant region.

13. (Previously Presented) The method of claim 12, wherein the chimeric antibody binds to an epitope included in amino acid residues of about 87-108 (SEQ ID NO:1) or about 59-80 (SEQ ID NO:2) of hTNF $\alpha$ .
14. (Previously Presented) The method of claim 12, wherein the chimeric antibody is monoclonal antibody cA2.
15. (Previously Presented) The method of claim 12, wherein the chimeric antibody competitively inhibits binding of TNF $\alpha$  to monoclonal antibody cA2.
- 16-36. (Cancelled)
37. (Previously Presented) The method of claim 34, wherein the chimeric antibody is monoclonal antibody cA2.
- 38-50. (Cancelled)
51. (Previously Presented) The method of claim 6, wherein the thrombosis is deep vein thrombosis.
52. (Cancelled)
53. (New) The method of claim 6 wherein the thrombotic disorder is a cardiovascular disorder selected from the group consisting of: acute myocardial infarction, deep vein thrombosis, and thrombophlebitis.